Current Research Studies

A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy

OMS721-HCT-002 Narsopliamb

Condition(s): BMT
Phase: II
Clinicaltrials.gov ID: NCT05855083

What is the goal of the study?

The purpose of this Phase 2 study is to evaluate the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of narsoplimab in paediatric-aged patients with thrombotic microangiopathies (TMA) following haematopoietic stem cell transplant (HSCT).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Sangeeta Hingorani
Study Team Member: Caroline Sandbo, [email protected]